Top

Published in:

01-01-2021 | Magnetic Resonance Imaging | Case report

First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with EGFR mutation as the initial and solitary site of postoperative recurrence

Authors: Yuki Ono, Kazuki Takada, Atsushi Osoegawa, Fumihiko Kinoshita, Taro Oba, Shuichi Tsukamoto, Tetsuzo Tagawa, Yoshinao Oda, Masaki Mori

Published in: International Cancer Conference Journal | Issue 1/2021

Abstract

Leptomeningeal metastasis (LM) from lung cancer has poor prognosis, and effective therapy has not been established. We present the case of a 54-year-old man with LM from lung adenocarcinoma harboring EGFR L858R point mutation, who received osimertinib as first-line therapy. He had previously undergone left lower lobectomy and lymph node dissection for lung adenocarcinoma. Five years and 9 months after the operation, he developed symptoms of dizziness, lightheadedness, and headache. Magnetic resonance imaging showed high signal intensity in the cerebral sulcus and meninges, and cerebrospinal fluid (CSF) cytology indicated adenocarcinoma with EGFR L858R point mutation, which suggested LM. After CSF drainage and administration of corticosteroid and glycerol, the patient received osimertinib (80 mg/day) as first-line therapy. These symptoms including dizziness, lightheadedness, and headache were relieved and the MRI appearance was normal, and he survived for 19 months with no disease progression. Osimertinib is considered to be an effective therapeutic option for LM from lung adenocarcinoma harboring EGFR mutation.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139CrossRef

Hata A, Katakami N, Kaji R, Fujita S, Imai Y (2012) Erlotinib for whole-brain-radiotherapy-refractory leptomeningeal metastases after gefitinib failure in a lung adenocarcinoma patient. J Thorac Oncol 7(4):770–771. https://doi.org/10.1097/JTO.0b013e31824c96bc ((Internet))CrossRefPubMed

Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D et al (2018) Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 118(1):32–37. https://doi.org/10.1038/bjc.2017.394 ((Internet))CrossRefPubMed

Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K et al (2012) Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 77(1):134–139. https://doi.org/10.1016/j.lungcan.2012.03.002 ((Internet))CrossRefPubMed

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. https://doi.org/10.1016/S1470-2045(09)70364-X ((Internet))CrossRefPubMed

Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 10(12):1754–1761. https://doi.org/10.1097/JTO.0000000000000669 ((Internet))CrossRefPubMed

Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB et al (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11(11):1962–1969. https://doi.org/10.1016/j.jtho.2016.06.029 ((Internet))CrossRefPubMed

Kwon BS, Cho YH, Yoon SK, Lee DH, Kim SW, Kwon DH et al (2020) Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. Thorac Cancer 11(2):436–442CrossRef

Chalmers A, Jensen L, Akerley W (2017) Lung cancer durable response to osimertinib in EGFR mutated T790M wildtype non- small cell lung cancer with leptomeningeal metastases: a case report. Lung Cancer 114(May):68–69. https://doi.org/10.1016/j.lungcan.2017.10.009 ((Internet))CrossRefPubMed

10.

Niu H, Niu J, Zhou J, Maan H, Markman M (2017) Treatment of leptomeningeal metastases in a patient with non-small cell lung cancer harboring EGFR T790M mutation. Case Rep Oncol 85234:840–845CrossRef

11.

Sakai H, Hayashi H, Iwasa T, Hasegawa Y, Takeda M, Nakagawa K (2016) Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR. ESMO Open 1(6):2016–2018

12.

Takeda T, Itano H, Takeuchi M, Nishimi Y, Saitoh M, Takeda S (2017) Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases. Respirol Case Reports 5(4):1–3CrossRef

13.

Chen J, Soudy H (2019) Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. Chinese Clin Oncol 8(3):6–11CrossRef

14.

Yang JCH, Kim S, Kim D, Lee J (2020) Osimertinib in patients with epidermal growth factor receptor mutation – positive non – small-cell lung cancer and leptomeningeal metastases: The BLOOM Study abstract. J Clin Oncol 38(6):538–547CrossRef

15.

Ahn M, Chiu C, Cheng Y, Crawford J, Zhao Y, Huang X et al (2020) Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 15(4):637–648. https://doi.org/10.1016/j.jtho.2019.12.113CrossRefPubMed

16.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 376(7): 629–640.

17.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A et al (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 36(33):3290–3297. https://doi.org/10.1200/JCO.2018.78.3118 ((Internet))CrossRef

18.

Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ et al (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4(9):1046–1061CrossRef

19.

Ballard P, Yates JWT, Yang Z, Kim DW, Yang JCH, Cantarini M et al (2016) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22(20):5130–5140CrossRef

20.

Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada T, Mochizuki S et al (2016) High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget 7(4):3847–3856CrossRef

Title: First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with EGFR mutation as the initial and solitary site of postoperative recurrence
Authors: Yuki Ono
Kazuki Takada
Atsushi Osoegawa
Fumihiko Kinoshita
Taro Oba
Shuichi Tsukamoto
Tetsuzo Tagawa
Yoshinao Oda
Masaki Mori
Publication date: 01-01-2021
Publisher: Springer Singapore
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Lung Cancer
Metastasis
Lung Cancer
CSF Drainage
Headache
Lung Cancer
Afatinib
Erlotinib
Gefitinib
Osimertinib
Published in: International Cancer Conference Journal / Issue 1/2021
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-020-00453-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Pitfall in the diagnosis of Lynch syndrome

A case of inferior right hepatic vein–right hepatic vein bypass with interrupted inferior vena cava compressed by focal nodular hyperplasia in caudate lobe

Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma

Gastric glomus tumor with a preoperative diagnosis by endoscopic ultrasonography-guided fine needle aspiration: a case report

Successful treatment of advanced pancreatic leiomyosarcoma treated with gemcitabine plus nab-paclitaxel: a case report and literature review

Abscopal complete regression of hepatocellular carcinoma with multiple pleural metastases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer